<?xml version="1.0" encoding="UTF-8"?>
<p>A recent appraisal of approval procedures for NBCD follow-on products approved in Europe shows a diversity of regulatory pathways being followed. In fact, three different abridged application procedures—under European legislation—were followed: the generic application procedure of Article 10(1), the hybrid application procedure of Article 10(3), and the biosimilar application procedure of Article 10(4). In the latter case, there is a contrasting decision when compared with the FDA approach, where low-molecular weight heparins (LMWH) were compared as complex drugs rather than as biologics, which is how the EU approach views them. Three informed consent applications through Article 10(c) from innovator companies of glatiramer acetate and sevelamer carbonate were submitted after the approval of the first follow-on products. Furthermore, a number of well-established use applications [via Article 10(a)] were approved for iron sucrose and iron dextran complex (
 <xref rid="B4" ref-type="bibr">4</xref>).
</p>
